Increased Blood Plasminogen Activator Inhibitor-1 and Intercellular Adhesion Molecule-1 as Possible Risk Factors of Atherosclerosis in Werner Syndrome

Gerontology ◽  
1997 ◽  
Vol 43 (1) ◽  
pp. 43-52 ◽  
Author(s):  
Shunichi Murano ◽  
Atsumi Nakazawa ◽  
Ichiro Saito ◽  
Mio Masuda ◽  
Nobuhiro Morisaki ◽  
...  
Keyword(s):  
Risk Factors ◽  
Plasminogen Activator ◽  
Adhesion Molecule ◽  
Werner Syndrome ◽  
Plasminogen Activator Inhibitor ◽  
Intercellular Adhesion ◽  
Intercellular Adhesion Molecule ◽  
Intercellular Adhesion Molecule 1 ◽  
Plasminogen Activator Inhibitor 1 ◽  
Activator Inhibitor

scholarly journals Circulating Concentrations of Monocyte Chemoattractant Protein-1, Plasminogen Activator Inhibitor-1, and Soluble Leukocyte Adhesion Molecule-1 in Overweight/Obese Men and Women Consuming Fructose- or Glucose-Sweetened Beverages for 10 Weeks

2011 ◽  
Vol 96 (12) ◽  
pp. E2034-E2038 ◽  
Author(s):  
Chad L. Cox ◽  
Kimber L. Stanhope ◽  
Jean Marc Schwarz ◽  
James L. Graham ◽  
Bonnie Hatcher ◽  
...  
Keyword(s):  
Adhesion Molecule ◽  
Plasminogen Activator Inhibitor ◽  
Intercellular Adhesion Molecule ◽  
Intercellular Adhesion Molecule 1 ◽  
Plasminogen Activator Inhibitor 1 ◽  
Monocyte Chemoattractant Protein 1 ◽  
Reactive Protein ◽  
Sweetened Beverages ◽  
Activator Inhibitor ◽  
Pai 1

Abstract Context: Results from animal studies suggest that consumption of large amounts of fructose can promote inflammation and impair fibrinolysis. Data describing the effects of fructose consumption on circulating levels of proinflammatory and prothrombotic markers in humans are unavailable. Objective: Our objective was to determine the effects of 10 wk of dietary fructose or glucose consumption on plasma concentrations of monocyte chemoattractant protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1), E-selectin, intercellular adhesion molecule-1, C-reactive protein, and IL-6. Design and Setting: This was a parallel-arm study with two inpatient phases (2 wk baseline, final 2 wk intervention), conducted in a clinical research facility, and an outpatient phase (8 wk) during which subjects resided at home. Participants: Participants were older (40–72 yr), overweight/obese (body mass index = 25–35 kg/m2) men (n = 16) and women (n = 15). Interventions: Participants consumed glucose- or fructose-sweetened beverages providing 25% of energy requirements for 10 wk. Blood samples were collected at baseline and during the 10th week of intervention. Main Outcome Measures: Fasting concentrations of MCP-1 (P = 0.009), PAI-1 (P = 0.002), and E-selectin (P = 0.048) as well as postprandial concentrations of PAI-1 (P < 0.0001) increased in subjects consuming fructose but not in those consuming glucose. Fasting levels of C-reactive protein, IL-6, and intercellular adhesion molecule-1 were not changed in either group. Conclusions: Consumption of fructose for 10 wk leads to increases of MCP-1, PAI-1, and E-selectin. These findings suggest the possibility that fructose may contribute to the development of the metabolic syndrome via effects on proinflammatory and prothrombotic mediators.

scholarly journals The Role of Plasminogen Activator Inhibitor-1 in the Metabolic Syndrome and Its Regulation

2014 ◽  
Vol 3 (6) ◽  
pp. 36 ◽  
Author(s):  
Martha Phelan ◽  
David M. Kerins
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
The Metabolic Syndrome ◽  
Activator Inhibitor ◽  
Pai 1

<p>Obesity is a major risk factor for cardiovascular disease (CVD). Lipid abnormalities, hypertension, impaired glucose tolerance or diabetes, are cardiovascular risk factors that are frequently present in patients with obesity. Haemostatic and fibrinolytic disturbances are also considered to be important risk factors for CVD hence, a potential link between CVD, obesity and the metabolic syndrome arises. Regulation of the fibrinolytic system can occur at the level of plasminogen activators and plasminogen activator inhibitor-1 (PAI-1). PAI-1, a glycoprotein, is one of the most important inhibitors of fibrinolysis. Regulation of this serine protease inhibitor may have a beneficial effect on other conditions associated with the metabolic syndrome. Human adipose tissue is a source of PAI-1. PAI-1 production may in turn be controlled by a number of hormones and cytokines which are secreted by adipose tissue in addition to dietary factors. In this review we summarise the current knowledge regarding the role of altered fibrinolytic function in obesity, CVD and hence the metabolic syndrome. Regulatory factors including different dietary components, weight loss and dietary intervention will also be discussed.</p>

scholarly journals Plasminogen Activator Inhibitor 1 Activity and Other Coronary Risk Factors

2005 ◽  
Vol 11 (1) ◽  
pp. 55-61 ◽  
Author(s):  
Finn Edler von Eyben ◽  
Ejvind Mouritsen ◽  
Jan Holm ◽  
Paulius Montvilas ◽  
Georg Dimcevski ◽  
...  
Keyword(s):  
Risk Factors ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Coronary Risk Factors ◽  
Coronary Risk ◽  
Plasminogen Activator Inhibitor 1 ◽  
Activator Inhibitor

High levels of homocysteine, lipoprotein (a) and plasminogen activator inhibitor-1 are present in patients with abdominal aortic aneurysm

2005 ◽  
Vol 94 (11) ◽  
pp. 1094-1098 ◽  
Author(s):  
Rossella Marcucci ◽  
Betti Giusti ◽  
Giovanni Pratesi ◽  
Barbara Lari ◽  
Ilaria Sestini ◽  
...  
Keyword(s):  
Risk Factors ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Factor V Leiden Mutation ◽  
Lipoprotein A ◽  
Abdominal Aortic ◽  
Significant Difference ◽  
Activator Inhibitor ◽  
Pai 1

SummaryOver the last few years, there has been increasing interest in the investigation of the pathogenesis of AAA, and a role for some novel risk factors, in particular thrombophilic risk factors, has been suggested. The aim of this study was to evaluate a number of thrombophilic parameters in a large group of patients with AAA. In 438 patients with AAA, and in 438 healthy subjects, selected to be comparable for age and gender with patients and without instrumental evidence of AAA, a pattern of thrombophilic parameters [homocysteine (Hcy), lipoprotein (a) [Lp(a)], plasminogen activator inhibitor-1 (PAI-1), anticardiolipin antibodies (ACA), MTHFR C677T polymorphism, prothrombin gene G20210A variant and Factor V Leiden mutation] has been evaluated. A significant difference for Hcy, PAI-1 and Lp(a) plas-After adjustment for the traditional cardiovascular risk factors, a significant increased risk of having AAA has been observed for high levels of Hcy (OR: 7.8; p<0.0001), Lp(a) (OR: 2.4; p<0.0001) and PAI-1 (OR:3.2;p<0.0001). The association has been confirmed after exclusion of patients with other localization of atherosclerosis. Moreover, a significant association between larger abdominal aortic diameters and the number of thrombophilic parameters has been reported (r = 0.13; p = 0.005). In conclusion, a significant association between abnormal levels of some metabolic parameters related to thrombosis such as Hcy, Lp(a) and PAI-1 and AAA has been observed.

Sign in / Sign up

Export Citation Format

Share Document